Gilead Sciences (GILD)
NASDAQ:GILD
Want to see GILD full AI Analyst Report?
Earnings Data
Report Date
Jul 30, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-7.03Last Year’s EPS
2.01Same Quarter Last Year
Strong Buy
Based on 23 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong commercial and clinical momentum across core franchises—particularly HIV (including PrEP), oncology (Trodelvy), and the rapid Libdelzi launch—resulting in raised revenue guidance, improved EPS and high margins. At the same time, near-term financials are materially impacted by large upfront acquisition-related IPR&D charges and associated tax consequences, alongside expected seasonal and cell therapy revenue headwinds. Overall the company delivered strong operational execution and a strengthened pipeline, but shareholders face short-term headline earnings pressure from the transactions.Company Guidance
Top-line growth and raised full-year guidance
Total product sales excluding Veklury of $6.8B, up 8% year-over-year; including Veklury $6.9B, up 5% year-over-year. Management increased 2026 revenue ranges by $400M and raised base business guidance to $29.4B–$29.8B (5%–6% YoY growth) and total product sales guidance to $30.0B–$30.4B.
Robust HIV franchise and PrEP momentum
HIV sales of $5.0B, up 10% YoY. Biktarvy sales $3.4B, up 7% YoY and retaining >52% U.S. share. U.S. PrEP business grew 87% YoY; Descovy $807M, up 38% YoY; Yes2Go posted $166M in Q1 with a 72% sequential increase and guidance raised to ~$1.0B for 2026 (from $800M). Company now expects full-year HIV sales to grow ~8% YoY.
Oncology momentum — Trodelvy and strategic acquisitions
Trodelvy sales $402M, up 37% YoY and 5% sequentially, with growing demand across breast cancer indications and NCCN category 1 recognition in first-line metastatic TNBC. Management expects regulatory decisions and multiple Phase 3 readouts in H2 2026. Tubulis acquisition adds TUB-40 (promising platinum-resistant ovarian-cancer data) and a differentiated ADC platform.
Successful specialty launches — Libdelzi
Libdelzi generated $133M in Q1 (more than tripled YoY) and now holds >50% share of the U.S. second-line PBC market; IDEAL Phase 3 update expected in H2 2026 that could expand the label/addressable population.
Profitability, margins, and shareholder returns
Product gross margin of 87% (up 2 percentage points YoY). Non-GAAP diluted EPS of $2.03, up 12% YoY. Operating margin of 47%. Returned >$1.4B to shareholders in Q1 (including >$400M of share repurchases) and returned ~60% of free cash flow to shareholders.
Broad and advancing pipeline
Pipeline expanded to 47 clinical programs after closing Arcellx (April 28) and pending acquisitions of Oral Medicines and Tubulis. Key upcoming regulatory and clinical milestones: Biclen priority FDA review decision expected in August 2026, anitocel PDUFA in December 2026, bulevirtide decision later this quarter, and multiple Phase 3 updates across HIV and oncology in 2026.
Strategic cell therapy positioning for anitocel
Arcellx acquisition brings anitocel with differentiated efficacy/safety into Kite; management targets an initial revenue contribution in early 2027 and cites a $3.5B fourth-line-plus CAR-T market opportunity. IMagine-3 enrollment is ahead of expectations.
GILD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GILD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $134.06 | $131.33 | -2.04% |
Feb 10, 2026 | $146.40 | $154.92 | +5.82% |
Oct 30, 2025 | $117.00 | $118.33 | +1.14% |
Aug 07, 2025 | $108.19 | $117.14 | +8.28% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Gilead Sciences (GILD) report earnings?
Gilead Sciences (GILD) is schdueled to report earning on Jul 30, 2026, After Close (Confirmed).
What is Gilead Sciences (GILD) earnings time?
Gilead Sciences (GILD) earnings time is at Jul 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GILD EPS forecast?
GILD EPS forecast for the fiscal quarter 2026 (Q2) is -7.03.